BR112017022158A2 - compostos, composições farmacêuticas e uso de um composto - Google Patents
compostos, composições farmacêuticas e uso de um compostoInfo
- Publication number
- BR112017022158A2 BR112017022158A2 BR112017022158A BR112017022158A BR112017022158A2 BR 112017022158 A2 BR112017022158 A2 BR 112017022158A2 BR 112017022158 A BR112017022158 A BR 112017022158A BR 112017022158 A BR112017022158 A BR 112017022158A BR 112017022158 A2 BR112017022158 A2 BR 112017022158A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical compositions
- compounds
- compound
- pi3k
- phosphoinositide
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 108091007960 PI3Ks Proteins 0.000 abstract 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
a presente invenção se refere a compostos que inibem fosfoinositida 3-cinase (pi3k), para composições farmacêuticas que as compreendem e à utilização terapêutica dos mesmos no tratamento de distúrbios associados com enzimas pi3k.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15163902 | 2015-04-16 | ||
EP15163902.8 | 2015-04-16 | ||
PCT/EP2016/058261 WO2016166239A1 (en) | 2015-04-16 | 2016-04-14 | Chromene derivatives as phoshoinositide 3-kinases inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112017022158A2 true BR112017022158A2 (pt) | 2018-07-03 |
BR112017022158B1 BR112017022158B1 (pt) | 2024-01-09 |
Family
ID=52991512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017022158-6A BR112017022158B1 (pt) | 2015-04-16 | 2016-04-14 | Compostos, composições farmacêuticas e uso de um composto |
Country Status (12)
Country | Link |
---|---|
US (1) | US9968604B2 (pt) |
EP (1) | EP3283481B1 (pt) |
KR (1) | KR20170137127A (pt) |
CN (1) | CN107454902B (pt) |
AR (1) | AR104262A1 (pt) |
BR (1) | BR112017022158B1 (pt) |
CA (1) | CA2982631A1 (pt) |
HK (1) | HK1246779A1 (pt) |
MX (1) | MX2017013137A (pt) |
RU (1) | RU2722383C2 (pt) |
TR (1) | TR201907614T4 (pt) |
WO (1) | WO2016166239A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019071144A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | USE OF P38 INHIBITORS TO REDUCE DUX4 EXPRESSION |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
PE20210169A1 (es) | 2017-10-18 | 2021-01-29 | Incyte Corp | Derivados de imidazol condensados sustituidos por grupos de hidroxia terciaria como inhibidores de pi3k-y gamma |
MX2020008814A (es) | 2018-02-27 | 2020-12-11 | Artax Biopharma Inc | Derivados de cromeno como inhibidores de la interaccion receptor de antigeno de celula t (tcr) - region no catalitica de la proteina citosolica de la proteina tirosina cinasa (nck). |
DK3847175T3 (da) | 2018-09-05 | 2024-03-18 | Incyte Corp | Krystallinske former af en phosphoinositid-3-kinase- (pi3k) inhibitor |
PL3947384T3 (pl) | 2019-04-04 | 2024-03-25 | Chiesi Farmaceutici S.P.A. | Pochodne izochromenu jako inhibitory kinaz 3-fosfoinozytydów |
CN111346095B (zh) * | 2020-03-14 | 2021-06-08 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | 用于治疗神经外科术后头痛的药物制剂 |
CN114891005B (zh) * | 2022-03-30 | 2024-01-19 | 武汉九州钰民医药科技有限公司 | 一种乌帕利斯对甲苯磺酸盐的制备工艺 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2772761B1 (fr) | 1997-12-23 | 2000-05-26 | Lipha | Nouveaux derives de n-phenylamide et n-pyridylamide, leur procede de preparation et compositions pharmaceutiques les contenant |
FR2797874B1 (fr) | 1999-08-27 | 2002-03-29 | Adir | Nouveaux derives de la pyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
PL371319A1 (en) | 2002-01-11 | 2005-06-13 | Takeda Pharmaceutical Company Limited | Coumarin derivatives, process for their production and use thereof |
DE102007018072A1 (de) | 2007-04-17 | 2008-10-30 | Volkswagen Ag | Anzeigeeinrichtung für ein Fahrzeug zum Anzeigen von den Betrieb des Fahrzeugs betreffende Informationen und Verfahren zum Anzeigen dieser Informationen |
AU2010316780B2 (en) * | 2009-11-05 | 2015-07-16 | Rhizen Pharmaceuticals Sa | Novel benzopyran kinase modulators |
ES2379242B1 (es) * | 2010-09-28 | 2013-03-04 | Consejo Superior De Investigaciones Científicas (Csic) | Derivados de cromeno. |
CN102746281B (zh) * | 2011-04-22 | 2015-01-14 | 四川大学 | 4-1,2,3-三氮唑-香豆素衍生物及其制备方法和用途 |
MY168757A (en) * | 2011-05-04 | 2018-12-04 | Rhizen Pharmaceuticals S A | Novel compounds as modulators of protein kinases |
JP6315848B2 (ja) | 2013-03-13 | 2018-04-25 | ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン | Mek/pi3k二重阻害剤および該阻害剤を使用する治療方法 |
TWI672297B (zh) | 2013-12-18 | 2019-09-21 | 義大利商吉斯藥品公司 | 作為磷脂肌醇-3-激酶抑制劑之異唏衍生物 |
-
2016
- 2016-03-24 US US15/079,740 patent/US9968604B2/en active Active
- 2016-04-14 AR ARP160101019A patent/AR104262A1/es unknown
- 2016-04-14 WO PCT/EP2016/058261 patent/WO2016166239A1/en active Application Filing
- 2016-04-14 MX MX2017013137A patent/MX2017013137A/es active IP Right Grant
- 2016-04-14 CA CA2982631A patent/CA2982631A1/en not_active Abandoned
- 2016-04-14 TR TR2019/07614T patent/TR201907614T4/tr unknown
- 2016-04-14 CN CN201680021995.7A patent/CN107454902B/zh not_active Expired - Fee Related
- 2016-04-14 RU RU2017134899A patent/RU2722383C2/ru active
- 2016-04-14 KR KR1020177031451A patent/KR20170137127A/ko unknown
- 2016-04-14 EP EP16720054.2A patent/EP3283481B1/en active Active
- 2016-04-14 BR BR112017022158-6A patent/BR112017022158B1/pt active IP Right Grant
-
2018
- 2018-05-09 HK HK18106024.7A patent/HK1246779A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
KR20170137127A (ko) | 2017-12-12 |
US9968604B2 (en) | 2018-05-15 |
HK1246779A1 (zh) | 2018-09-14 |
EP3283481B1 (en) | 2019-03-13 |
BR112017022158B1 (pt) | 2024-01-09 |
WO2016166239A1 (en) | 2016-10-20 |
EP3283481A1 (en) | 2018-02-21 |
RU2722383C2 (ru) | 2020-05-29 |
MX2017013137A (es) | 2018-02-21 |
RU2017134899A (ru) | 2019-05-16 |
RU2017134899A3 (pt) | 2019-06-17 |
CA2982631A1 (en) | 2016-10-20 |
TR201907614T4 (tr) | 2019-06-21 |
CN107454902B (zh) | 2020-09-15 |
US20160303123A1 (en) | 2016-10-20 |
CN107454902A (zh) | 2017-12-08 |
AR104262A1 (es) | 2017-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016028845A2 (pt) | composto, composição farmacêutica e uso de um composto | |
CO2017011851A2 (es) | Compuestos novedosos | |
BR112017022158A2 (pt) | compostos, composições farmacêuticas e uso de um composto | |
BR112018005497A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
BR112019001607A2 (pt) | inibidores macrocíclicos de quinases | |
BR112016020199A8 (pt) | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
BR112016015706A8 (pt) | composto, uso do mesmo e composição farmacêutica | |
NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
BR112016015838A8 (pt) | compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação | |
BR112018071408A2 (pt) | “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação | |
UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
BR112015011456A2 (pt) | compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m | |
UY35210A (es) | Inhibidores de autotaxina | |
ECSP12012318A (es) | Inhibidores de pirazolil quinazolina cinasa | |
BR112018070123A2 (pt) | oxiesterós e métodos de uso dos mesmos | |
BR112015030385A8 (pt) | composto, composto para uso e composição farmacêutica | |
BR112019021867A2 (pt) | Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil | |
UY36875A (es) | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades | |
BR112016019592A8 (pt) | Composto, uso de um composto, e, composição farmacêutica | |
UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
BR112018005905A2 (pt) | ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto? | |
ECSP14013275A (es) | Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
DOP2015000005A (es) | Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos | |
BR112016006388A2 (pt) | inibidor seletivo da fosfatidilinositol 3-quinase gama | |
BR112017002852A2 (pt) | compostos de azetidiniloxifenilpirrolidina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/04/2016, OBSERVADAS AS CONDICOES LEGAIS |